Connect with us

Hi, what are you looking for?

Alive Business PlanAlive Business Plan

Stock

RBC starts Oracle at Neutral on competition concerns

Investing.com — RBC Capital analysts initiated coverage of Oracle Corporation (NYSE:ORCL) with a Sector Perform rating and a $165 price target, expressing concerns about rising competition and the sustainability of some recent growth drivers.

“While we like Oracle’s market leadership position in database and ongoing cloud transformation, we have concerns about competition and the sustainability of some recent growth drivers, particularly OCI and GenAI,” RBC wrote.

Oracle’s core database business remains a key asset, according to the bank, but they believe it faces mounting challenges from multiple fronts.

Competition on multiple fronts continues to get stronger, including hyperscale cloud vendors (AWS/Azure/GCP), MongoDB (NASDAQ:MDB), PostgreSQL, and NewSQL vendors, RBC noted.

The firm added that while pricing may support growth, Oracle’s net new workload growth could be limited moving forward.

Oracle Cloud Infrastructure (OCI) has shown impressive growth, reaching $8.6 billion in annual recurring revenue (ARR) with a 54% growth rate, according to RBC estimates.

However, analysts remain cautious about the future of OCI.

“We have concerns over the sustainability of this growth, especially for non-Oracle customers,” RBC wrote, adding skepticism that OCI can become “the fourth hyperscaler,” especially given its much smaller size compared to competitors like AWS and Azure.

RBC also highlighted Oracle Fusion as one of the company’s more promising growth engines, particularly within financials.

“Customers view the product favorably, and partners believe the product remains ahead of the competition,” the analysts wrote. However, they expect Workday (NASDAQ:WDAY) Financials to close the gap over time.

Although the firm is bullish on generative AI (GenAI) technology, it is skeptical of Oracle’s ability to capture significant value from it.

“Our checks support our skepticism on Oracle’s GenAI announcements, especially when compared to the innovation taking place at Microsoft (NASDAQ:MSFT),” RBC noted.

With Oracle trading at all-time highs of around $175, RBC’s price target of $165 reflects a more cautious outlook, citing Oracle’s “relatively slower EPS growth” compared to peers.

This post appeared first on investing.com
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    The Gateway Pundit, a far-right website, published a note from its editor on Saturday acknowledging that two election workers in Georgia did not engage...

    Latest News

    New majorities in Congress, particularly when the incoming party has a new leader, offer the rare chance for the institution to take a breath...

    Latest News

    Vice President Kamala Harris’s doctor said in a letter Saturday that she is in “excellent health” as she released her first medical report in...

    Latest News

    Donald Trump is leaning into a nativist, anti-immigrant message in the final stage of his third presidential campaign, advancing a closing argument centered on...



    Disclaimer: alivebusinessplan.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 alivebusinessplan.com